Narcolepsy drug trial halted early: what happened?

NCT ID NCT06179407

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an experimental drug called MK-6552 in 9 people with narcolepsy type 1, a condition that causes sudden sleep attacks. The goal was to see if the drug was safe and could help patients stay awake during the day. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

narcolepsy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bogan Sleep Consultants ( Site 0001)

    Columbia, South Carolina, 29201, United States

  • Delta Waves, Inc. ( Site 0008)

    Colorado Springs, Colorado, 80918, United States

  • FutureSearch Trials of Neurology ( Site 0004)

    Austin, Texas, 78731, United States

  • NeuroTrials Research Inc ( Site 0006)

    Atlanta, Georgia, 30328, United States

  • Teradan Clinical Trials, LLC ( Site 0005)

    Brandon, Florida, 33511, United States